Multidrug treatment prevents the evolution of drug resistance
the verdict
REFUTED
the evidence says no
confidence 0/100
While multidrug regimens are commonly deployed to slow or manage resistance, they do not universally prevent its evolution, as numerous clinical and laboratory studies demonstrate that pathogens and cancer cells consistently find pathways to develop resistance under multi-agent pressure.
Evidence against · 5
Long-Term Effectiveness of combination Antiretroviral Therapy and Drug Resistance Patterns Among People living with HIV in Benghazi, Libya: Retrospective cohort Study (2009 – 2014)
2026 · cited by 0
This study demonstrates that despite the use of combination antiretroviral therapy, significant rates of multidrug resistance still emerge and persist in clinical settings.
See more details
More against · 4
Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.
2026 · cited by 0
The paper explains that cancer cells undergoing combination targeted therapies can adapt and increase their mutation rates, ultimately evolving into resistant phenotypes.
A telomerase-SUCLG2 signaling axis drives drug resistance by protecting persister cells.
2026 · cited by 0
Research shows that persister cells can survive combined targeted therapies and evolve into fully drug-resistant clones via telomerase and metabolic adaptations.
From Empirical Discovery to Targeted Therapy: The Evolution of Tuberculosis Treatment.
2026 · cited by 0
The review notes that despite long-standing guidelines requiring multidrug treatment for tuberculosis, the emergence and spread of drug-resistant strains continue to erode clinical efficacy.
Burn Wound Infections With Staphylococcus aureus: Clinical Characteristics and Risk Factors for Methicillin-Resistant Strains.
2026 · cited by 0
Multivariate analysis in this clinical study identifies the use of multiple antibiotic types as an independent risk factor for selecting multidrug-resistant bacterial infections.